Shares of Summit Therapeutics SMMT rose more than 15% on Friday after the analysts at Cantor Fitzgerald and Truist Securities ...

Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

Shares of lung cancer-focused biotech Summit Therapeutics ( SMMT 10.72%) rallied 16.6% at its highs of the day before ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

More importantly, the index is down a massive 13.8% so far this year. Summit Therapeutics is a clinical-stage biotech company ...

Summit Therapeutics Inc.’s SMMT share price has surged by 5.60%, which has investors questioning if this is right time to sell.

We recently published a list of 10 Firms Buck Thursday’s Market Bloodbath. In this article, we are going to take a look at ...

Some start successful businesses. Others invest in stocks that deliver explosive gains. Summit Therapeutics (NASDAQ: SMMT) is one of those stocks that have been quite explosive: The share price of ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

Others invest in stocks that deliver explosive gains. We can explain Summit Therapeutics' remarkable stock performance with just one word: ivonescimab. That's the cancer drug Summit licensed from ...